CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 36 enrolled
Drug / intervention
turoctocog alfa pegol (N8-GP)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05082116
NCT05082116Phase 3Completed
CompareCT.gov

A Multi-centre, Open-label Trial Evaluating Efficacy, Safety and Pharmacokinetics of Turoctocog Alfa Pegol (N8-GP) When Used for Treatment and Prophylaxis of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

Novo Nordisk A/S·interventional·Posted Oct 18, 2021·Updated Jan 6, 2026

In Brief

A Phase 3 clinical trial evaluating turoctocog alfa pegol (N8-GP) for Haemophilia A. Completed, enrolled 36 participants across 11 sites.

Detailed Summary

The study investigates how well the medicine called turoctocog alfa pegol (N8-GP) works in previously treated Chinese patients with severe haemophilia A. Participants will be treated with N8-GP. This is a medicine that doctors can already prescribe in other countries. The medicine will be injected into a vein (intravenous injections) and blood samples will be collected. The study will last for about 7-8 months. Participants will have between 8 and 15 visits to the clinic and possibly a number of phone calls with the study doctor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHaemophilia A
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedOct 18, 2021
Enrollment StartSep 27, 2021
Primary CompletionDec 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.7 years ago

Interventions

turoctocog alfa pegol (N8-GP)drug

N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks